Lars Dyrskjøt

22.5k total citations · 1 hit paper
189 papers, 9.7k citations indexed

About

Lars Dyrskjøt is a scholar working on Molecular Biology, Surgery and Cancer Research. According to data from OpenAlex, Lars Dyrskjøt has authored 189 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Molecular Biology, 109 papers in Surgery and 70 papers in Cancer Research. Recurrent topics in Lars Dyrskjøt's work include Bladder and Urothelial Cancer Treatments (108 papers), Urinary and Genital Oncology Studies (48 papers) and Epigenetics and DNA Methylation (41 papers). Lars Dyrskjøt is often cited by papers focused on Bladder and Urothelial Cancer Treatments (108 papers), Urinary and Genital Oncology Studies (48 papers) and Epigenetics and DNA Methylation (41 papers). Lars Dyrskjøt collaborates with scholars based in Denmark, United States and Netherlands. Lars Dyrskjøt's co-authors include Torben F. Ørntoft, Michael Borre, Mogens Kruhøffer, Marie S. Ostenfeld, Jens Ledet Jensen, Karin Birkenkamp‐Demtröder, Thomas Thykjær, Claus L. Andersen, Philippe Lamy and Niels Marcussen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Lars Dyrskjøt

177 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bladder cancer

2023 212 citations Lars Dyrskjøt, Margaret A. Knowles et al. profile →

Peers

Lars Dyrskjøt

SURGE

PRM

ONCOL

Brett S. Carver United States

Bogdan Czerniak United States

Donald P. Bottaro United States

Yves Allory France

Ellen C. Zwarthoff Netherlands

Yae Kanai Japan

Mireia Castillo-Martín United States

Mattias Höglund Sweden

Ermanno Gherardi United Kingdom

Cory Abate‐Shen United States

Brett S. Carver United States

Lars Dyrskjøt

4.6k ×0.7

2.9k ×0.7

1.7k ×0.5

SURGE

3.8k ×2.2

PRM

1.1k ×0.8

ONCOL

Citations per year, relative to Lars Dyrskjøt Lars Dyrskjøt (= 1×) peers Brett S. Carver

Countries citing papers authored by Lars Dyrskjøt

Since Specialization

Citations

This map shows the geographic impact of Lars Dyrskjøt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Dyrskjøt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Dyrskjøt more than expected).

Fields of papers citing papers by Lars Dyrskjøt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Dyrskjøt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Dyrskjøt. The network helps show where Lars Dyrskjøt may publish in the future.

Co-authorship network of co-authors of Lars Dyrskjøt

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Dyrskjøt. A scholar is included among the top collaborators of Lars Dyrskjøt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Dyrskjøt. Lars Dyrskjøt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okholm, Trine Line Hauge, Morten Muhlig Nielsen, Anne Kruse Hollensen, et al.. (2024). circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA. eLife. 13. 4 indexed citations

Jensen, Jørgen Bjerggaard, Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2024). 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial. Annals of Oncology. 35. S1133–S1133. 15 indexed citations

Nordentoft, Iver, Sia V. Lindskrog, Philippe Lamy, et al.. (2023). Improved protocol for single-nucleus RNA-sequencing of frozen human bladder tumor biopsies. Nucleus. 14(1). 2186686–2186686. 2 indexed citations

Hensley, Patrick J., Roland Seiler, Harry W. Herr, et al.. (2023). Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1. Urologic Oncology Seminars and Original Investigations. 41(7). 307–312. 1 indexed citations

Christensen, Emil, Iver Nordentoft, Karin Birkenkamp‐Demtröder, et al.. (2023). Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 29(8). 1582–1591. 36 indexed citations

Lindskrog, Sia V., Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2023). Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clinical Cancer Research. 29(23). 4797–4807. 26 indexed citations

Sokač, Mateo, Johanne Ahrenfeldt, Kevin Litchfield, et al.. (2022). Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer. Cancer Research Communications. 2(8). 762–771. 12 indexed citations

Kanellis, Dimitris C., Jaime A. Espinoza, Elpidoforos Sakkas, et al.. (2021). The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Science Advances. 7(32). 45 indexed citations

Azawi, Nessn, et al.. (2020). The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomised Controlled Trial. European Urology. 78(6). 856–862. 21 indexed citations

10.

Prip, Frederik, Brent T. Harris, David A. Solomon, et al.. (2018). STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 24(17). 4145–4153. 24 indexed citations

11.

Lamy, Philippe, Iver Nordentoft, Karin Birkenkamp‐Demtröder, et al.. (2016). Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Research. 76(19). 5894–5906. 68 indexed citations

12.

Kandimalla, Raju, Roy Masius, Willemien Beukers, et al.. (2013). A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine. Clinical Cancer Research. 19(17). 4760–4769. 51 indexed citations

13.

Reinert, Thomas, Charlotte Modin, Philippe Lamy, et al.. (2011). Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers. Clinical Cancer Research. 17(17). 5582–5592. 169 indexed citations

14.

Dyrskjøt, Lars, Marie S. Ostenfeld, Jesper B. Bramsen, et al.. (2009). Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro. Cancer Research. 69(11). 4851–4860. 315 indexed citations

15.

Sørensen, Karina D., Peter J. Wild, Ashkan Mortezavi, et al.. (2009). Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research. 15(4). 1400–1410. 25 indexed citations

16.

Schepeler, Troels, Thomas Reinert, Marie S. Ostenfeld, et al.. (2008). Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Research. 68(15). 6416–6424. 419 indexed citations

17.

Dyrskjøt, Lars, Karsten Zieger, Francisco X. Real, et al.. (2007). Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. Clinical Cancer Research. 13(12). 3545–3551. 154 indexed citations

18.

Aaboe, Mads, Karin Birkenkamp‐Demtröder, Carsten Wiuf, et al.. (2006). SOX4 Expression in Bladder Carcinoma: Clinical Aspects and In vitro Functional Characterization. Cancer Research. 66(7). 3434–3442. 137 indexed citations

19.

Zieger, Karsten, Lars Dyrskjøt, Carsten Wiuf, et al.. (2005). Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors. Clinical Cancer Research. 11(21). 7709–7719. 76 indexed citations

20.

Dyrskjøt, Lars, Karsten Zieger, Mogens Kruhøffer, et al.. (2005). A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome. Clinical Cancer Research. 11(11). 4029–4036. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact